Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06779630 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
A NA study of Coronary Artery Disease, sponsored by Teleflex.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 15
- Study locations
NCT06779630: Recruiting NA study of Coronary Artery Disease, sponsored by Teleflex.
NCT06779630 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Teleflex. The registered enrollment target is 150 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The trial reports 15 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06779630, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Teleflex.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm. Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patients enrolled outside of the United States will be followed through 5 years post index procedure with additional follow-up visits at 3 and 5 years post index procedure.
Primary Outcome
The primary endpoint will be target lesion failure (TLF) rate at 12 months post-index procedure. TLF is defined as a composite of cardiac death, target vessel Q-wave or non-Q-wave myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR).
Conditions Studied
Interventions
- DEVICE Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
Study Locations (15)
Texas
- Baylor Scott & White The Heart Hospital - Dallas - Dallas
- Ascension Texas Cardiovascular - Kyle
California
- John Muir Medical Center - Concord
Kansas
- Ascension Via Christi Hospitals Wichita - Wichita
New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital - New York
West Virginia
- Charleston Area Medical Center - Charleston
Styria
- Klinische Abteilung für Kardiologie, Medizinische Universität Graz - Graz
Vienna
- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie, Medizinische Universität Wien - Vienna
Provence-Alpes-Côte d'Azur Region
- Institut Arnault Tzanck - Saint-Laurent-du-Var
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2031-09 |
| Phase | NA |
What NCT06779630 shows while recruiting
NCT06779630 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System is the first listed.
NCT06779630 lists 15 locations in 14 states (Texas, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT06779630 about?
NCT06779630 is a clinical study titled "Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions". The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel d...
What is the current status of trial NCT06779630?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-07-18. Estimated completion is 2031-09.
What conditions does trial NCT06779630 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT06779630?
The interventions under investigation include: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT06779630?
This trial is sponsored by Teleflex, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06779630 being conducted?
This trial has 15 study locations across California, Kansas, New York, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06779630's enrollment target sits among peer trials
150 130th of 219 higher than 87 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI